Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00935818 · ClinicalTrials.gov registry record · Phase 2
Varenicline and Bupropion for Smoking Cessation
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 506
- Enrollment target
NCT00935818: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00935818 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 506 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00935818, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 506 participants
- Enrollment target
Study Summary
This study provides an opportunity to combine varenicline and bupropion SR and capitalize on the potential additive benefit. The investigators hypothesize that this will further increase long-term (≥ 6 months) smoking abstinence rates.
Interventions
- DRUG placebo
- DRUG Varenicline
- DRUG bupropion SR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 506 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00935818
The ClinicalTrials.gov registry entry for NCT00935818 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 506 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00935818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00935818 about?
NCT00935818 is a clinical study titled "Varenicline and Bupropion for Smoking Cessation". This study provides an opportunity to combine varenicline and bupropion SR and capitalize on the potential additive benefit. The investigators hypothesize that this will further increase long-term (≥ 6 months) smoking abstinence rates.
What is the current status of trial NCT00935818?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 506 participants. The study started on 2009-09. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00935818?
The interventions under investigation include: placebo (DRUG), Varenicline (DRUG), bupropion SR (DRUG).
Who is sponsoring clinical trial NCT00935818?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.